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Background
Development, evaluation and optimisation of HIV-1
genetic vaccine components to generate a large pool of
CD8+ T cell memory cells recognising multiple cytotoxic
lymphocyte (CTL) epitopes is one of the primary strate-
gies in anti-HIV-1 vaccination protocols. This project, as
part of the Patterson VDC/CAVD consortium http://
www.cavd.org, aims to develop viral 'stealth'/non-viral
vector vaccines against HIV-1 by targeting skin dendritic
cells (DC).
We aimed to induce immunity to HIV-1 infection by
developing a cohort of vectors in which HIV-1 and SIV
vaccine components have been engineered and modified
to stimulate broader CTL responses through genetic frag-
mentation and ubiquitination.
Methods
Full-size codon optimised HIV-1 and SIV gag genes were
fused to mono- or tetra-ubiquitin (Ub) sequences and
tested on DC and non-DC cell lines and compared to their
native, non-ubiquitinated forms. Recombinant adenovi-
ral vectors (rAds) were produced and used in these exper-
iments. In parallel, we tested the stability of the Ub
sequences within the context of rAd vector development.
We subsequently constructed rAds carrying genetically
fragmented ubiquitinated versions for both HIV and SIV
gag genes in an attempt to reduce antigenic competition
and alter epitope dominance.
Results
Ubiquitin fusion resulted in efficient proteasomal target-
ing of Gag compared to the degradation rate in its
absence, as shown by experiments involving the proteaso-
mal blocking agent MG132. The tetra-Ub sequence was
shown to be unstable during rAd vector propagation
whereas mono-Ub versions of antigens were efficiently
created and currently undergoing extensive in vitro and in
vivo testing.
Conclusion
We are extending our studies using an in vitro CTL epitope-
mapping system employing human monocyte-derived
DC from healthy and HIV-1+ individuals alongside
mouse in vivo studies in order to investigate the effect of
antigen ubiquitination and fragmentation on the quality
of the generated immune response. Additionally, the SIV
constructs will be tested in a non-human primate chal-
lenge model (cynomolgus macaque).
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